Medicaid

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests

CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement.CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO),...

Vital Data Technology Announces Agreement with Mid-State Health Network to Provide Predictive Models for Mental Health and Substance Use Disorders

NEWPORT BEACH, Calif., Dec. 10, 2024 /PRNewswire/ -- Vital Data Technology, a leading provider of AI-driven health data analytics and...

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

- Data from long-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY™ -...

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease...

error: Content is protected !!